<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01946009</url>
  </required_header>
  <id_info>
    <org_study_id>GESIDA-7412</org_study_id>
    <nct_id>NCT01946009</nct_id>
  </id_info>
  <brief_title>A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients</brief_title>
  <acronym>CIDAN12</acronym>
  <official_title>A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cidofovir could be an effective drug for the treatment of Anal Intraepithelial
      Neoplasia(AIN).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with complete regression of anal intraepithelial neoplasia</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe the percentage of patients achieving complete regression of anal intraepithelial neoplasia (AIN), as confirmed by means of high-resolution anoscopy and biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the percentage of patients that reduce the degree of Anal dysplasia</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe the percentage of patients that reduce the degree of Anal dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe the percentage of patients with recurrence after complete regression of HSIL and median time to relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clear of Human papillomavirus</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe the percentage of patients in whom Human Papillomavirus clears after treatment with cidofovir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe the number of patients with adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment effect</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prospective Clinical Trial exploratory nature of the effect of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cidofovir 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.</intervention_name>
    <arm_group_label>Cidofovir 1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               1. Patients who have given informed consent in writing of the study before making
                  any specific selection procedure for the study.

               2. Adult patients (18 years) with documented HIV infection, with high-grade AIN
                  demonstrated by biopsy, and have not received any prior treatment for Anal
                  Intraepithelial Neoplasia in the last 12 weeks.

               3. For women of childbearing potential, negative pregnancy test in urine screening
                  visit. All women of childbearing age should continue effective contraception
                  throughout the study treatment.

          -  Exclusion Criteria:

             1. Patients who have received previous treatment of Anal Intraepithelial Neoplasia
             (AIN) in the last 12 weeks. 2. Dermatoses in patients with anogenital area 3.
             Patients with a history of pre-invasive neoplasia associated with Human Papilloma
             Virus 4. Patients with a history of previous neoplasm, of any origin and location, in
             the past 5 years.

             5. Patients with a history of hematologic abnormalities, kidney or liver 6. Pregnant
             or breastfeeding women or women of childbearing age who do not wish to use adequate
             contraception at the discretion of the investigator.

             7. Any disease or condition of the patient which, in the opinion of the investigator,
             is not adequate patient participation in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Sendagorta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cidofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
